Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical & Experimental Metastasis
Published in: Clinical & Experimental Metastasis 5/2010

01-05-2010 | Research Paper

The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action

Authors: Chih-Min Yang, Yi-Zih Liu, Jiunn-Wang Liao, Miao-Lin Hu

Published in: Clinical & Experimental Metastasis | Issue 5/2010

Login to get access

Abstract

This study examined the anti-metastatic effects of oxythiamine (OT) both in cell culture and in vivo. Cell culture results revealed that OT (0–20 μM) significantly inhibited the invasion and migration (IC50 = 8.75 μM) of Lewis lung carcinoma (LLC) cells. These effects of OT were accompanied by the inhibition of metalloproteinases-2 and -9 (MMP-2, MMP-9), urokinase-type plasminogen activator (uPA) activities and by the increases in protein expression of tissue inhibitors of metalloproteinases-1 and -2 (TIMP-1, TIMP-2). We then implanted (s.c.) C57BL/6 mice with LLC cells and supplemented the mice with a low- or a high-dose of OT (250 or 500 mg/kg BW) daily for 5 wk. During the 5-wk period, OT supplementation decreased plasma MMP-2 activity in a dose-dependent manner, and this effect was significant after 4 wk of tumor cell implantation. Tumor metastasis was found to confine to the lungs of mice injected with the tumor cells. High-OT supplementation strongly lowered the number and area of tumors and inhibited protein expression of MMP-2 and MMP-9 in the lungs. In addition, high-OT supplementation markedly decreased the extent of proliferating cell nuclear antigen (PCNA) staining in the lungs. By contrast, OT supplementation increased TIMP-1 and -2 protein expression in the lungs. These results demonstrate that OT supplementation attenuates tumor cell metastasis, possibly via inhibition of protein expression of MMPs, extent of PCNA staining and via increase of proteins expression of TIMPs.
Literature
1.
Weinstat-Saslow D, Steeg PS (1994) Angiogenesis and colonization in the tumor metastatic process: basic and applied advances. FASEB J 8:401–407PubMed
2.
Westermarck J, Kahari VM (1999) Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 13:781–792PubMed
3.
Bjorklund M, Koivunen E (2005) Gelatinase-mediated migration and invasion of cancer cells. Biochim Biophys Acta 1755:37–69PubMed
4.
Boros LG, Brandes JL, Yusuf FI, Cascante M, Williams RD, Schirmer WJ (1998) Inhibition of the oxidative and nonoxidative pentose phosphate pathways by somatostatin: a possible mechanism of antitumor action. Med Hypotheses 50:501–506CrossRefPubMed
5.
Basu TK, Dickerson JW (1976) The thiamin status of early cancer patients with particular reference to those with breast and bronchial carcinomas. Oncology 33:250–252CrossRefPubMed
6.
Boros LG, Brandes JL, Lee WN, Cascante M, Puigjaner J, Revesz E, Bray TM, Schirmer WJ, Melvin WS (1998) Thiamine supplementation to cancer patients: a double edged sword. Anticancer Res 18:595–602PubMed
7.
Chornyy S, Parkhomenko J, Chorna N (2007) Thiamine deficiency caused by thiamine antagonists triggers upregulation of apoptosis inducing factor gene expression and leads to caspase 3-mediated apoptosis in neuronally differentiated rat PC-12 cells. Acta Biochim Pol 54:315–322PubMed
8.
Boros LG, Puigjaner J, Cascante M, Lee WN, Brandes JL, Bassilian S, Yusuf FI, Williams RD, Muscarella P, Melvin WS, Schirmer WJ (1997) Oxythiamine and dehydroepiandrosterone inhibit the nonoxidative synthesis of ribose and tumor cell proliferation. Cancer Res 57:4242–4248PubMed
9.
Rais B, Comin B, Puigjaner J, Brandes JL, Creppy E, Saboureau D, Ennamany R, Lee WN, Boros LG, Cascante M (1999) Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich’s tumor cells through inhibition of the pentose cycle. FEBS Lett 456:113–118CrossRefPubMed
10.
Ramos-Montoya A, Lee WN, Bassilian S, Lim S, Trebukhina RV, Kazhyna MV, Ciudad CJ, Noe V, Centelles JJ, Cascante M (2006) Pentose phosphate cycle oxidative and nonoxidative balance: a new vulnerable target for overcoming drug resistance in cancer. Int J Cancer 119:2733–2741CrossRefPubMed
11.
Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65:55–63CrossRefPubMed
12.
Repesh LA (1989) A new in vitro assay for quantitating tumor cell invasion. Invasion Metastasis 9:192–208PubMed
13.
Kleiner DE, Stetler-Stevenson WG (1994) Quantitative zymography: detection of picogram quantities of gelatinases. Anal Biochem 218:325–329CrossRefPubMed
14.
15.
Duffy MJ, McCarthy K (1998) Matrix metalloproteinases in cancer: prognostic markers and targets for therapy (review). Int J Oncol 12:1343–1348PubMed
16.
Itoh T, Tanioka M, Yoshida H, Yoshioka T, Nishimoto H, Itohara S (1998) Reduced angiogenesis and tumor progression in gelatinase A-deficient mice. Cancer Res 58:1048–1051PubMed
17.
Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH (2007) Inhibition of angiogenesis and invasion by 3,3′-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67:3310–3319CrossRefPubMed
18.
Liabakk NB, Talbot I, Smith RA, Wilkinson K, Balkwill F (1996) Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 56:190–196PubMed
19.
Bloomston M, Zervos EE, Rosemurgy AS II (2002) Matrix metalloproteinases and their role in pancreatic cancer: a review of preclinical studies and clinical trials. Ann Surg Oncol 9:668–674CrossRefPubMed
20.
Watanabe M, Takahashi Y, Ohta T, Mai M, Sasaki T, Seiki M (1996) Inhibition of metastasis in human gastric cancer cells transfected with tissue inhibitor of metalloproteinase 1 gene in nude mice. Cancer 77:1676–1680PubMed
21.
Nagase H (1997) Activation mechanisms of matrix metalloproteinases. Biol Chem 378:151–160PubMed
22.
Iwata H, Kobayashi S, Iwase H, Okada Y (1995) The expression of MMPs and TIMPs in human breast cancer tissues and importance of their balance in cancer invasion and metastasis. Nippon Rinsho 53:1805–1810PubMed
23.
Kawamata H, Kawai K, Kameyama S, Johnson MD, Stetler-Stevenson WG, Oyasu R (1995) Over-expression of tissue inhibitor of matrix metalloproteinases (TIMP1 and TIMP2) suppresses extravasation of pulmonary metastasis of a rat bladder carcinoma. Int J Cancer 63:680–687CrossRefPubMed
24.
Bravo R, Frank R, Blundell PA, Macdonald-Bravo H (1987) Cyclin/PCNA is the auxiliary protein of DNA polymerase-delta. Nature 326:515–517CrossRefPubMed
25.
Weber KL, Doucet M, Price JE, Baker C, Kim SJ, Fidler IJ (2003) Blockade of epidermal growth factor receptor signaling leads to inhibition of renal cell carcinoma growth in the bone of nude mice. Cancer Res 63:2940–2947PubMed
26.
Robbins BA, de la Vega D, Ogata K, Tan EM, Nakamura RM (1987) Immunohistochemical detection of proliferating cell nuclear antigen in solid human malignancies. Arch Pathol Lab Med 111:841–845PubMed
27.
Liu JF, Lo A, Yang FL, Wang TY, Cheng CM, Shaw NS, Kao MD, Chuang CY, Huang CJ (2002) Analysis of vitamin E, selenium, and other nutrients in planed balanced diets in Taiwan. Nutr Sci J 27:221–231
Metadata
Title
The in vitro and in vivo anti-metastatic efficacy of oxythiamine and the possible mechanisms of action
Authors
Chih-Min Yang
Yi-Zih Liu
Jiunn-Wang Liao
Miao-Lin Hu
Publication date
01-05-2010
Publisher
Springer Netherlands
Published in
Clinical & Experimental Metastasis / Issue 5/2010
Print ISSN: 0262-0898
Electronic ISSN: 1573-7276
DOI
https://doi.org/10.1007/s10585-010-9331-2

Other articles of this Issue 5/2010

Clinical & Experimental Metastasis 5/2010 Go to the issue

Research Paper

Localization of osteoblast inflammatory cytokines MCP-1 and VEGF to the matrix of the trabecula of the femur, a target area for metastatic breast cancer cell colonization

Research Paper

NGAL knockdown by siRNA in human cholangiocarcinoma cells suppressed invasion by reducing NGAL/MMP-9 complex formation

Review

The in vitro and in vivo experimental evidences disclose the chemopreventive effects of Ganoderma lucidum on cancer invasion and metastasis

Research Paper

Gender difference in bone metastasis of human small cell lung cancer, SBC-5 cells in natural killer-cell depleted severe combined immunodeficient mice

Research Paper

Characterization of a new renal cell carcinoma bone metastasis mouse model

Research Paper

Cationic liposome coupled endostatin gene for treatment of peritoneal colon cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits